Vinge has represented the international private equity firm Cinven in connection with its acquisition of the Säkra group (“Säkra”).

Säkra, with about 350 insurance professionals across 60 offices throughout Sweden, provides tailor-made insurance solutions, occupational pension plans and advisory services, and is one of the leading insurance intermediaries in Sweden. The acquisition of Säkra marks the fourth investment from Cinven’s inaugural Strategic Financials Fund (‘SFF’).

The SFF builds on Cinven’s leading financial services investment platform in Europe with an investment strategy focused on areas where Cinven has developed significant investment expertise, such as life and non-life insurance and reinsurance, asset-backed speciality finance, wealth management, insurance distributors and other ‘capital light’ tech-enabled financial service providers.

The acquisition is subject to approvals from the Swedish Financial Supervisory Authority and the Swedish Competition Authority.

Vinge's team consisted mainly of Christina Kokko, Samra Baytar, Carl Fredrik Wachtmeister and Robin Fagerström (M&A), Viveka Classon and Fabian Ekeblad (Corporate Insurance), Emma Stuart-Beck, Caroline Krassén, Henrik Schön and David Flodin (Financial Services), Hedvig Ekdahl (Commercial Agreements), Kristoffer Larsson (Real Estate), Louise Brorsson Salomon, Kamyar Najmi and Ellen Flygt (Banking and Finance), Rebecka Målquist (IP), Nicklas Thorgerzon (IT and GDPR) Sara Strandberg (Employment), David Olander and Victoria Fredén (ECR), and Emy Rydén (project assistant).

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025